Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fufang Banmao Capsule plus EGFR-TKI versus EGFR-TKI alone in advanced EGFR-mutant non-small cell lung cancer after prior EGFR-TKI with stable disease
ChiCTR1900024240Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fufang banmao capsule, gefitinib and erlotinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900024240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024240.